Investors
Proprietary PrecisionMedicine Platformfor Dermatology &Inflammatory Diseases
- Non-invasive sampling
- Protein-level immune biomarkers
- AI-powered treatment selection
Psoriasis
$466M
annual U.S. switching cost
Eczema
$3.7B
annual U.S. switching cost
Expansion
Multi-disease
skin, GI, and immune-mediated disorders
Value creation
Clear benefits across the ecosystem.
Patients
- •Lower cost burden
- •Improved outcomes
Healthcare Providers
- •Faster decisions
- •Less treatment cycling
Pharma
- •Biomarker-defined trials
- •Companion diagnostic path
Payors
- •Reduced waste
- •Evidence-based utilization
Market expansion
Dermatology first. Broader inflammation next.
Atopic dermatitis
Psoriasis
Alopecia areata
Hidradenitis suppurativa
Lupus
Inflammatory bowel disease